Trials / Completed
CompletedNCT04597593
Association Between Genetic Variant Scores and DOACs (DARES2)
Correlation Between Bleeding Complication and Treatment Failure of DOAC and Its Predictions Based on Cipherome's Pharmacogenomic Technology
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (actual)
- Sponsor
- Cipherome, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study's objective is to evaluate the predictive accuracy of Cipherome's algorithm in predicting and preventing serious adverse drug reactions (ADRs) experienced by patients while on direct oral anti-coagulants (DOACs).
Conditions
Timeline
- Start date
- 2020-10-07
- Primary completion
- 2022-12-29
- Completion
- 2022-12-30
- First posted
- 2020-10-22
- Last updated
- 2023-08-16
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04597593. Inclusion in this directory is not an endorsement.